Sotorasib

Sotorasib (AMG 510) is a targeted therapy used to treat non-small cell lung cancer (NSCLC) that has a mutation in the KRAS gene. It is a type of therapy called a KRAS-G12C inhibitor. It works by blocking proteins that signal tumor growth. Sotorasib is used to treat adults with metastatic NSCLC whose tumors have a KRAS G12C mutation and have progressed after prior treatment. It is taken as a pill once a day.

Sotorasib, sold under brand names Lumakras and Lumykras, targets a specific type of lung cancer. Here's a breakdown of its key aspects:

What it is:

• Sotorasib is a medication classified as a KRAS inhibitor.
• KRAS stands for Kirsten rat sarcoma viral oncogene homolog, a protein involved in cell growth and proliferation. Mutations in this protein can contribute to uncontrolled cell growth and cancer development.

Medical use:

• Sotorasib is specifically indicated for adults with KRAS G12C-mutated non-small cell lung cancer (NSCLC).
  • Non-small cell lung cancer (NSCLC) is the most common type of lung cancer.
  • The G12C mutation occurs in a specific part of the KRAS gene.
• It's typically used for patients who have already received at least one other treatment for their lung cancer (second-line therapy).

How it works:

• Sotorasib targets the KRAS G12C mutation, blocking the abnormal protein's signaling pathway. This disrupts the uncontrolled growth of cancer cells.

Important to know:

• Sotorasib is a prescription medication and requires a doctor's diagnosis to confirm the specific type of lung cancer and KRAS mutation suitable for this treatment.
• It comes in tablet form and is usually taken once daily.
• Like any medication, Sotorasib can cause side effects. Common ones include diarrhea, nausea, vomiting, fatigue, and rash.
• It can interact with other medications, so it's crucial to inform your doctor about all medications you're taking.

Here are some additional points to consider:

• Sotorasib is a relatively new and promising treatment for KRAS G12C-mutated NSCLC.
• It's not a cure, but it can help manage the condition and potentially improve outcomes.
• Clinical trials are ongoing to evaluate Sotorasib's efficacy in combination with other therapies or for earlier treatment stages.